Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a cholesterol drug help Kids' hearts after kawasaki disease?

NCT ID NCT07530640

Recruiting now Disease control Sponsor: Children's Hospital of Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial is testing whether atorvastatin, a common cholesterol drug, is safe and can reduce inflammation in children with Kawasaki disease who also have coronary artery abnormalities. The study will enroll 9 children and give them different doses of atorvastatin for 6 weeks. Researchers will monitor side effects and measure changes in inflammation markers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
atorvastatin (a statin drug, typically used to lower cholesterol)
What this could lead to
If it works, this could point toward a way to reduce heart artery damage in children with Kawasaki disease.
What could go wrong
This is a very small, early-phase trial (only 9 participants) focused on safety, so it may not prove effectiveness. Statins can cause muscle or liver side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY ABNORMALITIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery congenital malformation Kawasaki disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY ABNORMALITIES KAWASAKI DISEASE

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Fudan University

    RECRUITING

    Shanghai, 201102, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.